Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

This trial is testing whether a medication called AGB101 (a low dose of levetiracetam, a drug also used for epilepsy) can safely reduce hallucinations, delusions, and other psychotic symptoms in people with Parkinson's disease. **You may be eligible if...** - You are 40–85 years old and have been diagnosed with Parkinson's disease - You experience hallucinations, delusions, illusions, or a false sense of someone being present at least once a week - These symptoms have been happening for at least one month and started after your Parkinson's diagnosis - You have a partner or caregiver who spends at least 2 hours per week with you - You are on a stable Parkinson's medication regimen for at least 4 weeks - You are willing and able to have MRI scans **You may NOT be eligible if...** - You have severe kidney problems or are on dialysis - You have another brain condition such as Alzheimer's, Huntington's, or a seizure disorder - You have a pre-existing diagnosis of schizophrenia, bipolar disorder, or another psychotic disorder unrelated to Parkinson's - You have had deep brain stimulation surgery - You have taken anticonvulsant medications in the past month - You are currently pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.